Clinical trial
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's…
NCT00055640 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00055640 |
|---|---|
| Title | Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma |
| Official title | Molecular Risk Guided Treatment Of Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Genetic |
| Interventions | rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, microarray analysis |
| Enrollment | 9 |
| Start date | Oct 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Mar 7, 2003 |
| Last update posted | Jun 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: